Advertisement
Screener

uniQure N.V. (QURE) Overview

uniQure N.V. (QURE) Overview

  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.85; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -1.38; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -0.69; Beat / miss (m).
  • 1 Jan 2025: Period ending 31 Mar 2025; Estimate (m); Actual -0.82; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$8.58$13.20$20.32$31.28$48.15$74.122025-09-292026-09-29$3.59$6.58$12.05$22.08$40.46$74.122021-09-292026-09-29$3.59$6.78$12.81$24.19$45.69$86.302016-09-292026-09-29$3.59$6.78$12.81$24.19$45.69$86.302014-02-052026-09-29$3.59$6.78$12.81$24.19$45.69$86.302014-02-052026-09-29

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$24.51
Previous close
$39.11
Change
-$14.60
Change (%)
-37.33%
Close date
2026-09-29
Previous close date
2026-09-28
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

QURE
+2.42%
S&P 500
(m)

1 year

QURE
-58.74%
S&P 500
(m)

3 years

QURE
+265.28%
S&P 500
(m)

5 years

QURE
-22.22%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

31 Mar 2026 ○ Estimate (m) ● Actual -0.85

-1.46-1.22-0.98-0.75-0.5130 Sept 2024: estimate (m); actual -0.9130 Sept 2024(m)31 Mar 2025: estimate (m); actual -0.8231 Mar 2025(m)30 Jun 2025: estimate (m); actual -0.6930 Jun 2025(m)30 Sept 2025: estimate (m); actual -1.3830 Sept 2025(m)31 Mar 2026: estimate (m); actual -0.8531 Mar 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202631 Mar 2026(m)-0.85(m)(m)
1 Jul 202530 Sept 2025(m)-1.38(m)(m)
1 Apr 202530 Jun 2025(m)-0.69(m)(m)
1 Jan 202531 Mar 2025(m)-0.82(m)(m)
1 Jul 202430 Sept 2024(m)-0.91(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -3.46

-6.55-3.110.333.787.2231 Dec 2021: estimate (m); actual 7.0431 Dec 2021(m)31 Dec 2022: estimate (m); actual -2.7131 Dec 2022(m)31 Dec 2023: estimate (m); actual -6.4731 Dec 2023(m)31 Dec 2024: estimate (m); actual -4.9231 Dec 2024(m)31 Dec 2025: estimate (m); actual -3.4631 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-3.46(m)(m)
1 Jan 202431 Dec 2024(m)-4.92(m)(m)
1 Jan 202331 Dec 2023(m)-6.47(m)(m)
1 Jan 202231 Dec 2022(m)-2.71(m)(m)
1 Jan 202131 Dec 2021(m)7.04(m)(m)

Revenue vs. Earnings

USD

31 Mar 2026 ■ Revenue 3.56M ■ Earnings -53.53M — Profit margin -1502.95%

-60.39M-2785.7%-36.79M-2357.8%-13.19M-1929.9%10.41M-1501.9%31 Mar 2025: revenue 1.57M; earnings -43.64M; profit margin -2784.75%31 Mar 202531 Mar 2026: revenue 3.56M; earnings -53.53M; profit margin -1502.95%31 Mar 2026

No complete retained periods.

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$24.51(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$24.51High(m)Average(m)Low(m)2025-09-292026-09-29

Recent news

View more →

(m)

YouTube videos mentioning QURE

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending (m).

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
(m)
Profit margin
(m)
Return on assets · 12 month
(m)
Stock compensation expense · all employees · 12 months
(m)
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
221.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
2.85M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-45.87%*
Total return · month
-49.69%*
Total return · quarter
-48.28%*
Total return · half year
65.94%*
Total return · year to date
2.42%*
Total return · 1 year
-58.74%*
Total return · 3 years
265.28%*
Total return · 5 years
-22.22%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
(m)
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

uniQure N.V. Overview

View more →

(m)

(m)

SEC CIK
1590560
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
Netherlands
Business address
PAASHEUVELWEG 25A, AMSTERDAM, Netherlands, 1105 BP, Netherlands
Fiscal year end
1231
Phone
1-339-970-7000

Similar stocks

Stock NameCountryMarket CapPE Ratio
SELLAS Life Sciences Group, Inc. (SLS)United States$2.420B-91.87
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67
Harmony Biosciences Holdings, Inc. (HRMY)United States$2.399B11.67
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
Mineralys Therapeutics, Inc. (MLYS)United States$2.353B-6.82
Viridian Therapeutics, Inc.\DE (VRDN)United States$2.342B-5.38
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Immunome Inc. (IMNM)United States$2.538B-9.45
Disc Medicine, Inc. (IRON)United States$2.553B-11.40
Zai Lab Ltd (ZLAB)$2.241B-113.34